The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus vaccine to adults ages 50 to 59 who are at increased risk of getting severely sick from the virus.

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) in adults aged 18-49 at increased risk for ...

Contact her at [email protected] The Food and Drug Administration has approved giving GSK's vaccine for respiratory syncytial virus down to age 50 years old, to those who are at ...

Analysis-GSK, Pfizer RSV Vaccine Sales Fall in US as Millions Fewer People Line Up By Michael Erman (Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after ...

GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.

GSK will start preparations for regulatory filings of its respiratory syncytial virus (RSV) vaccine straight away, after the shot hit the mark in the much-anticipated AReSVi 006 trial in adults ...

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has ...

It was clear that GSK’s vaccine division would see lower sales this quarter. But sales of the RSV vaccine, called Arexvy, and the company’s shingles vaccine Shingrix were both below analysts ...

GSK Plc’s RSV vaccine has been approved for wider use in adults in Europe in a boost for the UK company’s blockbuster shot. The European Commission recommended GSK’s Arexvy for adults aged ...

Regulators narrowed the targeted age group for RSV vaccines Demand for RSV vaccines has fallen by up to two-thirds GSK maintains market lead despite reduced sales Some independent pharmacists said ...